A review of preserved and preservative-free prostaglandin analogues for the treatment of open-angle glaucoma and ocular hypertension

Drugs of Today

Volumn 46, Issue 6, 2010, Pages 409-416

  Hommer, Anton ^a  

^a Augenabteilung Sanatorium Hera   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BIMATOPROST; LATANOPROST; PROSTAGLANDIN DERIVATIVE; TAFLUPROST; TRAVOPROST; PRESERVATIVE; PROSTAGLANDIN F;

ADD ON THERAPY; BURNING SENSATION; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DRY EYE; EPIPHORA; EYELID DISEASE; FOREIGN BODY REACTION; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; IRIS DISEASE; OPEN ANGLE GLAUCOMA; PATIENT COMPLIANCE; PATIENT SATISFACTION; QUALITY OF LIFE; REVIEW; BLINDNESS; COMPLICATION; GLAUCOMA; GLAUCOMA, OPEN-ANGLE; HYPERSENSITIVITY; OCULAR HYPERTENSION;

BLINDNESS; GLAUCOMA; GLAUCOMA, OPEN-ANGLE; HUMANS; HYPERSENSITIVITY; OCULAR HYPERTENSION; PRESERVATIVES, PHARMACEUTICAL; PROSTAGLANDINS F; PROSTAGLANDINS F, SYNTHETIC; PROSTAGLANDINS, SYNTHETIC;

EID: 77955452998     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2010.46.6.1482107     Document Type: Review

References (39)

1. Quigley, H.A., Broman, A.T. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006, 90(3): 262-7.
2. Varma, R., Wu, J, Chong, K., Azen, S.P., Hays, R.D.; Los Angeles Latino Eye Study Group. Impact of severity and bilaterality of visual impairment on health-related quality of life. Ophthalmology 2006, 113(10): 1846-53.
3. McKean-Cowdin, R., Wang, Y., Wu, J., Azen, S.P., Varma, R.; Los Angeles Latino Eye Study Group. Impact of visual field loss on health-related quality of life in glaucoma: The Los Angeles Latino Eye Study. Ophthalmology 2008, 115(6): 941-8.
4. Ramulu, P. Glaucoma and disability: Which tasks are affected, and at what stage of disease? Curr Opin Ophthalmol 2009, 20(2): 92-8.
5. European Glaucoma Society. Terminology and guidelines for glaucoma (3rd edition). http://www.eugs.org/eng/EGS-guidelines.asp.
6. The AGIS investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000, 130(4): 429-40.
7. Leske, M.C., Heijl, A., Hussein, M., Bengtsson, B., Hyman, L., Komaroff, E.; Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: The Early Manifest Glaucoma Trial. Arch Ophthalmol 2003, 121(1): 48-56.
8. Kass, M.A., Heuer, D.K., Higginbotham, E.J. et al. The Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002, 120(6): 701-13.
9. Stewart, W.C., Garrison, P.M. Beta-blocker-induced complications and the patient with glaucoma. Newer treatments to help reduce systemic adverse events. Arch Intern Med 1998, 158(3): 221-6.
10. Mincione, F., Scozzafava, A., Supuran, C.T. The development of topically acting carbonic anhydrase inhibitors as antiglaucoma agents. Curr Pharm Des 2008, 14(7): 649-54.
11. Alm, A., Grierson, I., Shields, M.B. Side effects associated with prostaglandin analog therapy. Surv Ophthalmol 2008, 53(Suppt. 1): S93-105.
12. Honrubla, F., García-Sánchez, J., Polo, V., de la Casa, J.M., Soto, J. Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: A meta-analysis of randomized clinical trials. Br J Ophthalmol 2009, 93(3): 316-21.
13. Cracknell, K.P., Grierson, I. Prostaglandin analogues in the anterior eye: Their pressure lowering action and side effects. Exp Eye Res 2009, 88(4): 786-91.
14. Nordmann, J.P., Auzanneau, N., Ricard, S., Berdeaux, G. Vision-related quality of life and topical glaucoma treatment side-effects. Health Qual Life Outcomes 2003, 1: 75.
15. Tsai, J.C., McClure, C.A., Ramos, S.E., Schlundt, D.G., Pichert, J.W. Compliance barriers in glaucoma: A systematic classification. J Glaucoma 2003, 12(5): 393-8.
16. Day, D.G., Sharpe, E.D., Atkinson, M.J., Stewart, J.A., Stewart, W.C. The clinical validity of the treatment satisfaction survey for intraocular pressure in ocular hypertensive and glaucoma patients. Eye (Lond) 2006, 20(5): 583-90.
17. Zimmerman, T.J., Hahn, S.R., Gelb, L., Tan, H., Kim, E.E. The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: Changes in prescription patterns and patient persistence. J Ocul Pharmacol Ther 2009, 25(2): 145-52.
18. Konstas, A.G., Maskaleris, G., Gratsonidis, S., Sardelli, C. Compliance and viewpoint of glaucoma patients in Greece. Eye (Lond) 2000, 14(Pt. 5): 752-6.
19. Schwartz, G.F., Quigley, H.A. Adherence and persistence with glaucoma therapy. Surv Ophthalmol 2008, 53(Suppl. 1): S57-68.
20. Lachaine, J., Hodge, W.G., Steffensen, I. et al. Prostaglandin analogues for ophthalmic use: A cost-effectiveness analysis. Can J Ophthalmol 2008, 43(1): 33-41.
21. Sverrisson, T., Gross, R., Pearson, J., Rusk, C., Adamsons, I. The dorzolamide/timolol combination versus timolol plus pilocarpine: Patient preference and impact on daily life. United States Patient Preference Study Group. International Patient Preference Study Group. J Glaucoma 1999, 8(5): 315-24.
22. Baudouin, C. Detrimental effect of preservatives in eyedrops: Implications for the treatment of glaucoma. Acta Ophthalmol 2008, 86(7): 716-26.
23. Levrat, F., Pisella, P.J., Baudouin, C. Clinical tolerance of antiglaucoma eyedrops with and without a preservative. Results of an unpublished survey in Europe. J Fr Ophtalmol 1999, 22(2): 186-91.
24. Pisella, P.J., Pouliquen, P., Baudouin, C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol 2002, 86(4): 418-23.
25. Jaenen, N., Baudouin, C., Pouliquen, P., Manni, G., Figueiredo, A., Zeyen, T. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol 2007, 17(3): 341-9.
26. Bron, A., Chiambaretta, F., Pouliquen, P., Rigal, D., Rouland, J.F. Efficacy and safety of substituting a twice-daily regimen of timolol with a single daily instillation of nonpreserved beta-blocker in patients with chronic glaucoma or ocular hypertension. J Fr Ophtalmol 2003, 26(7): 668-74.
27. Sutton, A., Gilvarry, A., Ropo, A. A comparative, placebo-controlled study of prostanoid fluoroprostaglandin-receptor agonists tafluprost and latanoprost in healthy males. J Ocul Pharmacol Ther 2007, 23(4): 359-65.
28. Sutton, A., Gouws, P., Ropo, A. Tafluprost, a new potent prostanoid receptor agonist: A dose-response study on pharmacodynamics and tolerability in healthy volunteers. Int J Clin Pharmacol Ther 2008, 46(8): 400-6.
29. Uusitalo, H., Kaarniranta, K., Ropo, A. Pharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteers. Acta Ophthalmol Suppl (Oxf) 2008, 242: 7-13.
30. Hamacher, T., Airakslnen, J., Saarela, V., Liinamaa, M.J., Richter, U., Ropo, A. Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: Results from a pharmacodynamics analysis. Acta Ophthalmol Suppl (Oxf) 2008, 242: 14-19.
31. Uusitalo, H., Pillunat, L.E., Ropo, A. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-Month results of a randomized, double-masked phase III study. Acta Ophthalmol 2010, 88(1): 12-9.
32. Traverso, C.E., Ropo, A., Papadia, M., Uusitalo, H. A Phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of tafluprost compared with latanoprost. J Ocul Pharmacol Ther 2010, 26(1): 97-104.
33. van der Valk, R., Webers, C.A., Schouten, J.S., Zeegers, M.P., Hendrikse, F., Prins, M.H. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: A meta-analysis of randomized clinical trials. Ophthalmology 2005, 112(7): 1177-85.
34. Burstein, N.L. Preservative alteration of corneal permeability in humans and rabbits. Invest Ophthalmol Vis Sci 1984, 25(12): 1453-7.
35. Majumdar, S., Hippalgaonkar, K., Repka, M.A. Effect of chitosan, benzalkonium chloride and ethylenediaminetetraacetic acid on permeation of acyclovir across isolated rabbit cornea. Int J Pharm 2008, 348(1-2): 175-8.
36. Pellinen, P., Lokkila, J. Corneal penetration into rabbit aqueous humor is comparable between preserved and preservative-free tafluprost. Ophthalmic Res 2009, 41(2): 118-22.
37. Brasnu, E., Brignole-Baudouin, F., Riancho, L., Guenoun, J.M., Warnet, J.M., Baudouin, C. In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line. Curr Eye Res 2008, 33(4): 303-12.
38. Liang, H., Baudouin, C., Pauly, A., Brignole-Baudouin, F. Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride. Br J Ophthalmol 2008, 92(9): 1275-82.
39. Uusitalo, H., Chen, E., Pfeiffer, N. et al. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol 2010, 88(3): 329-36.